Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
Clinical trial NCT01754389 · COMPLETED
Trial details
- NCT number
- NCT01754389
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-01-01
- Primary completion
- 2016-05-01
- Enrollment
- 138
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.